Alectinib shows significantly improved efficacy in terms of progression-free survival (PFS) over crizotinib in the first-line setting, yet again, this time involving Asian patients with ALK+ NSCLC in the ALESIA* study, consistent with previous findings in a global population.
Treatment with the novel phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib, in combination with the selective oestrogen receptor degrader fulvestrant, nearly doubled progression-free survival (PFS) in advanced hormone receptor-positive (HR+) breast cancer with PIK3CA mutations, beating fulvestrant alone in the SOLAR-1 trial. Experts said this signals the dawn of precision medicine for breast cancer.
Adults newly diagnosed with mantle cell lymphoma who were unable to undergo bone marrow transplantation had longer overall survival (OS) following first-line treatment with VR-CAP* compared with R-CHOP**, according to final results of the phase III LYM-3002*** trial.
Adding the combination therapy of zoledronic acid + letrozole to triptorelin as adjuvant treatment for hormone receptor positive (HR+) early breast cancer in premenopausal women significantly improves disease-free survival (DFS) compared with the combination of tamoxifen and triptorelin, according to the HOBOE-2* study presented at ESMO 2018.
Final analysis of results from the PALOMA-3 study showed improvement in overall survival (OS) with addition of cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib to fulvestrant in hormone receptor−positive, HER2-negative advanced breast cancer that has relapsed or progressed on hormonal therapy.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.